Home > Items where lead contributor is Livingstone-Banks Jonathan

up arrow imageUp a level
Export as
Group by: Item Type | No Grouping
Jump to: Article
Number of items: 7.

Article

Livingstone-Banks, Jonathan (2023) Clinical question: How does bupropion compare with placebo for promoting smoking cessation in adolescents and adults? Cochrane Clinical Answers, DOI: 10.1002/cca.4339.

Livingstone-Banks, Jonathan (2023) Clinical question: How does bupropion compare with varenicline or nicotine replacement therapies (NRTs) for promoting smoking cessation in adolescents and adults? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4338.

Livingstone-Banks, Jonathan (2023) Clinical question: What are the effects of adding bupropion or fluoxetine to other treatments compared with using other treatments alone for people trying to quit smoking? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4337.

Livingstone-Banks, Jonathan (2023) Clinical question: What are the benefits and harms of opioid agonist treatment for people who are dependent on pharmaceutical opioids? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4180.

Livingstone-Banks, Jonathan and Lindson, Nicola and Hartmann-Boyce, Jamie and Aveyard, Paul (2022) Effects of interventions to combat tobacco addiction: Cochrane update of 2019 and 2020 reviews. Addiction, 117, (6), pp. 1526-1542. doi: 10.1111/add.15769.

Livingstone-Banks, Jonathan (2021) Clinical question: What are the benefits and harms of psychosocial interventions for reducing parental alcohol and drug misuse? Cochrane Clinical Answers, (2021), DOI: 10.1002/cca.3794.

Livingstone-Banks, Jonathan (2021) Clinical question: What are the effects of standardized tobacco packaging design in reducing tobacco use among adults? Cochrane Clinical Answers, https://doi.org/10.1002/cca.3527.

This list was generated on Fri Mar 29 03:52:23 2024 GMT.